zacks.com · 30 jun

New Strong Sell Stocks for June 30th

BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.

zacks.com · 29 jun

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

zacks.com · 29 jun

Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

globenewswire.com · 29 jun

Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Biogen, Inc. (NASDAQ: BIIB):   OKLAHOMA FIREFIGHTERS PENSION AND RETIREMENT SYSTEM,                                                        Plaintiff,                               v. BIOGEN INC.

globenewswire.com · 29 jun

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. Presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI® (lecanemab).

reuters.com · 26 jun

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs ​as it integrates the rare-disease drugs specialist it purchased ‌for $5.6 billion earlier this year.

zacks.com · 26 jun

Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.

prnewswire.com · 25 jun

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.